Months after investment, Bayer strikes option deal with Dewpoint in CV, women’s health

Less than a year after Leaps by Bayer invested in biomolecular condensates company Dewpoint, the corporate VC’s parent company has struck an option deal that broadens its access to the start-up’s technology.

Bayer AG (Xetra:BAYN) will hold an option to obtain exclusive, worldwide rights to a specific number of programs the companies will research jointly in the cardiovascular and gynecologic fields. Dewpoint Therapeutics CEO Amir Nashat declined to disclose specific terms, but the companies said Bayer’s contribution could reach $100 million...